Last updated: February 27, 2026
What is the drug associated with NDC 00093-7273?
NDC 00093-7273 is a formulation of Mepolizumab, marketed under the brand name Nucala. It is a monoclonal antibody designed to target interleukin-5 (IL-5), used primarily for severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis (EGPA).
Market Overview
Market Size and Patient Demographics
- Indications: Severe eosinophilic asthma, EGPA, hypereosinophilic syndrome.
- Prevalence: Approximately 150 million asthma patients globally, with severe cases representing 5-10%. Eosinophilic asthma accounts for around 30-40% of severe cases.
- Target Population: Estimated at 6-12 million globally.
Competitive Landscape
- Primary competitors: Dupilumab (Dupixent), Benralizumab (Fasenra), Reslizumab (Cinqair).
- Market share: Nucala holds ~40-50% of the IL-5 antagonist segment in the U.S., according to IQVIA data as of 2022.
- Pricing:
- U.S.: approximately $32,500 per injection (100 mg dose).
- Dosing frequency: Every 4 weeks for asthma; every 4–8 weeks for EGPA.
Regulatory Status and Approvals
- FDA: Approved for severe eosinophilic asthma, EGPA, hypereosinophilic syndrome.
- EMA: Approved with similar indications in Europe.
Trends and Drivers
- Growing demand due to increasing awareness and diagnosis of eosinophilic conditions.
- Expansion into new indications and populations (e.g., chronic obstructive pulmonary disease with eosinophilia).
- Biologics competition affects pricing and market share.
Price Projections
Current Pricing Dynamics
- Per-Unit Price: ~$32,500 per 100 mg injection in the U.S.
- Reimbursement: Insurance policies and PBMs heavily influence actual patient cost.
- Market Penetration Factors: Physician preference, patient adherence, and formulary inclusion.
Future Price Trends
Cost Analysis and Reimbursement
| Factor |
Effect on Price |
| Biosimilar entry |
Decreases prices by 20–40% |
| Increased competition |
Stabilizes or reduces prices |
| Expanded indications |
May sustain or slightly increase prices due to higher demand |
Market Risks and Opportunities
- Risks:
- Biosimilar threats.
- Pricing pressure from payers.
- Regulatory delays or label restrictions.
- Opportunities:
- Expansion into new indications.
- Geographic expansion, especially in emerging markets.
- Development of combo therapies to improve efficacy.
Summary of Financial Expectations
| Year |
Price Projection |
Market Penetration |
Revenue Forecast (Global) |
| 2023 |
~$32,500 per dose |
Steady, market leadership |
$2.0 billion |
| 2024 |
Slight decline (~5%) |
Increasing due to expanded use |
$1.9 billion |
| 2025 |
Biosimilar entry |
Potential 20-30% price drop |
$1.5–1.7 billion |
Key Takeaways
- NDC 00093-7273 (mepolizumab) is a leading biologic for eosinophilic asthma.
- The current price is approximately $32,500 per injection, with demand driven by severity and approval expansion.
- Biosimilar competition is imminent, with potential for significant price reductions by 2025.
- Market growth hinges on new indications, geographic expansion, and payer acceptance.
- Price stabilization is expected in mature markets, but biosimilar entry will likely reshape the landscape.
FAQs
Q1: When are biosimilars for mepolizumab expected to enter the market?
A1: Anticipated around 2025–2026, depending on regulatory approval and development progress.
Q2: How does the price of Nucala compare with similar biologics?
A2: It is comparable to other IL-5 antagonists like Benralizumab, with similar dosing and cost structures.
Q3: What factors could increase Nucala’s market share?
A3: Expanded indications, increased diagnosis of eosinophilic conditions, and favorable payer policies.
Q4: Will the price of Nucala decrease significantly in the next year?
A4: Likely a 5-10% decrease driven by market competition and payer negotiations.
Q5: How are insurance companies influencing Nucala’s pricing?
A5: Payers negotiate discounts and formulary placements, which can impact patient out-of-pocket costs and overall revenue.
References
[1] IQVIA. (2022). Pharmaceutical Market Data.
[2] U.S. Food and Drug Administration. (2023). Nucala (mepolizumab) prescribing information.
[3] European Medicines Agency. (2022). Assessment report for mepolizumab.
